APA (7th ed.) Citation

Michaeli, J., Michaeli, C. T., Trapani, D., Albers, S., Dannehl, D., Würstlein, R., & Michaeli, D. (2024). Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovation, trials, endpoints, quality of life, value, and price. Breast cancer, 31(6), . https://doi.org/10.1007/s12282-024-01634-x

Chicago Style (17th ed.) Citation

Michaeli, Julia, Christoph T. Michaeli, Dario Trapani, Sebastian Albers, Dominik Dannehl, Rachel Würstlein, and Daniel Michaeli. "Breast Cancer Drugs: FDA Approval, Development Time, Efficacy, Clinical Benefits, Innovation, Trials, Endpoints, Quality of Life, Value, and Price." Breast Cancer 31, no. 6 (2024). https://doi.org/10.1007/s12282-024-01634-x.

MLA (9th ed.) Citation

Michaeli, Julia, et al. "Breast Cancer Drugs: FDA Approval, Development Time, Efficacy, Clinical Benefits, Innovation, Trials, Endpoints, Quality of Life, Value, and Price." Breast Cancer, vol. 31, no. 6, 2024, https://doi.org/10.1007/s12282-024-01634-x.